Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
[accordions]
[accordion title= “Chemical Properties“]
Synonyms | Obinutuzumab/afutuzumab |
Molecular Weight | 150 kDa |
CAS No. | 949142-50-1 |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
[/accordion]